| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/25/2023 | 50.88% | HC Wainwright & Co. | $28 → $25 | Maintains | Buy |
| 12/14/2022 | -5.25% | UBS | → $15.7 | Initiates Coverage On | → Neutral |
| 08/18/2022 | 38.81% | Goldman Sachs | $14 → $23 | Upgrades | Neutral → Buy |
| 06/28/2022 | 20.7% | Cowen & Co. | $18 → $20 | Maintains | Outperform |
| 05/09/2022 | 20.7% | Cowen & Co. | $18 → $20 | Maintains | Outperform |
| 04/21/2022 | 75.02% | Wells Fargo | $27 → $29 | Maintains | Overweight |
| 02/28/2022 | 68.98% | HC Wainwright & Co. | $19 → $28 | Maintains | Buy |
| 11/23/2021 | 81.05% | Wolfe Research | → $30 | Upgrades | Peer Perform → Outperform |
| 11/23/2021 | 38.81% | Cowen & Co. | $12 → $23 | Upgrades | Market Perform → Outperform |
| 10/15/2021 | -33.61% | Goldman Sachs | $6 → $11 | Maintains | Neutral |
| 10/08/2021 | -33.61% | Wells Fargo | $8 → $11 | Maintains | Overweight |
| 10/04/2021 | 14.67% | HC Wainwright & Co. | → $19 | Initiates Coverage On | → Buy |
| 03/24/2021 | -51.72% | Wells Fargo | → $8 | Upgrades | Equal-Weight → Overweight |
| 12/15/2020 | -75.86% | Wells Fargo | → $4 | Downgrades | Overweight → Equal-Weight |
| 03/27/2020 | -93.96% | Goldman Sachs | $2 → $1 | Maintains | Neutral |
| 02/11/2020 | — | Raymond James | Upgrades | Underperform → Market Perform |
What is the target price for Calumet Specialty (CLMT)?
There is no price target for Calumet Specialty
What is the most recent analyst rating for Calumet Specialty (CLMT)?
There is no analyst for Calumet Specialty
When is the next analyst rating going to be posted or updated for Calumet Specialty (CLMT)?
There is no next analyst rating for Calumet Specialty
Is the Analyst Rating Calumet Specialty (CLMT) correct?
There is no next analyst rating for Calumet Specialty